Cargando…

Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials

Non-alcoholic steatohepatitis (NASH) results from inflammation and hepatocyte injury in the setting of hepatic steatosis. Non-alcoholic steatohepatitis increases the risk of progression to liver fibrosis and cirrhosis, and is the most rapidly growing etiology for liver failure and indication for liv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Connolly, James J., Ooka, Kohtaro, Lim, Joseph K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	XIA & HE Publishing Inc. 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160309/ https://www.ncbi.nlm.nih.gov/pubmed/30271738 http://dx.doi.org/10.14218/JCTH.2017.00056

Ejemplares similares

Non-Alcoholic Steatohepatitis (NASH) and Organokines: What Is Now and What Will Be in the Future
por: dos Santos, João Paulo Margiotti, et al.
Publicado: (2022)

The role of mitochondrial genomics in patients with non-alcoholic steatohepatitis (NASH)
por: Mehta, Rohini, et al.
Publicado: (2016)

Pharmaceutical Efficacy of Gypenoside LXXV on Non-Alcoholic Steatohepatitis (NASH)
por: Lee, Jin Ha, et al.
Publicado: (2020)

Drugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail
por: Sharma, Mithun, et al.
Publicado: (2021)

Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH)
por: Min-DeBartolo, Jessica, et al.
Publicado: (2019)

Molecular Mechanisms and New Treatment Strategies for Non-Alcoholic Steatohepatitis (NASH)
por: Takaki, Akinobu, et al.
Publicado: (2014)

Non-Alcoholic Steatohepatitis (NASH): Risk Factors in Morbidly Obese Patients
por: Losekann, Alexandre, et al.
Publicado: (2015)

A New Potential Strategy for Acute Non-Alcoholic Steatohepatitis (NASH)
por: Sekhon, Anupamjeet Kaur, et al.
Publicado: (2021)

Deficiency of WTAP in hepatocytes induces lipoatrophy and non-alcoholic steatohepatitis (NASH)
por: Li, Xinzhi, et al.
Publicado: (2022)

An Improved qFibrosis Algorithm for Precise Screening and Enrollment into Non-Alcoholic Steatohepatitis (NASH) Clinical Trials
por: Leow, Wei-Qiang, et al.
Publicado: (2020)

Analogy between non-alcoholic steatohepatitis (NASH) and hypertension: a stepwise patient-tailored approach for NASH treatment
por: Ilan, Yaron
Publicado: (2018)

Increased Expression of RUNX1 in Liver Correlates with NASH Activity Score in Patients with Non-Alcoholic Steatohepatitis (NASH)
por: Kaur, Savneet, et al.
Publicado: (2019)

Novel Combinatorial Regimen of Garcinol and Curcuminoids for Non-alcoholic Steatohepatitis (NASH) in Mice
por: Majeed, Muhammed, et al.
Publicado: (2020)

A Structured Literature Review of the Epidemiology and Disease Burden of Non-Alcoholic Steatohepatitis (NASH)
por: Povsic, Manca, et al.
Publicado: (2019)

Systematic analysis of randomised controlled trials of Chinese herb medicine for non-alcoholic steatohepatitis (NASH): implications for future drug development and trial design
por: Chen, Xianwen, et al.
Publicado: (2023)

Metabolomic Profiling to Identify Predictors of Response to Vitamin E for Non-Alcoholic Steatohepatitis (NASH)
por: Cheng, Jianfeng, et al.
Publicado: (2012)

Role of adipose tissue in methionine–choline-deficient model of non-alcoholic steatohepatitis (NASH)()
por: Jha, Pooja, et al.
Publicado: (2014)

Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model
por: Stefano, J.T., et al.
Publicado: (2015)

The Influence of Different Fat Sources on Steatohepatitis and Fibrosis Development in the Western Diet Mouse Model of Non-alcoholic Steatohepatitis (NASH)
por: Drescher, Hannah K., et al.
Publicado: (2019)

Evolving Role for Pharmacotherapy in NAFLD/NASH
por: Attia, Suzanna L., et al.
Publicado: (2020)

Role of microRNA in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a comprehensive review
por: Kan Changez, Mah I, et al.
Publicado: (2023)

Prevalence of Non Alcoholic Steatohepatitis (NASH) and association with body mass index in obese adolescents in Padang
por: Farlina, Lita, et al.
Publicado: (2013)

Multiple Hits, Including Oxidative Stress, as Pathogenesis and Treatment Target in Non-Alcoholic Steatohepatitis (NASH)
por: Takaki, Akinobu, et al.
Publicado: (2013)

Reliability and validity of the Chronic Liver Disease Questionnaire (CLDQ) in adults with non-alcoholic steatohepatitis (NASH)
por: Chawla, Kashmira S, et al.
Publicado: (2016)

Placental extract ameliorates non-alcoholic steatohepatitis (NASH) by exerting protective effects on endothelial cells
por: Yamauchi, Akihiro, et al.
Publicado: (2017)

Machine learning using longitudinal prescription and medical claims for the detection of non-alcoholic steatohepatitis (NASH)
por: Yasar, Ozge, et al.
Publicado: (2022)

Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis: Molecular and Multicellular Control of Evolving Diseased States
por: Eeckhoute, Jérôme
Publicado: (2022)

Economic Burden of Non-Alcoholic Steatohepatitis (NASH) Among Diabetic Population in Italy: Analysis and Perspectives
por: Torre, Enrico, et al.
Publicado: (2022)

Elastographic liver evaluation of Katukyadi churna in the management of Non-Alcoholic Steatohepatitis (NASH) – A single arm clinical trial.
por: Tarapure, Shruti, et al.
Publicado: (2021)

The Effects of Probiotics, Prebiotics and Synbiotics in Non-Alcoholic Fat Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review
por: Carpi, Rodrigo Zamignan, et al.
Publicado: (2022)

Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention
por: Tacke, Frank, et al.
Publicado: (2021)

Longitudinal analysis of a dietary mouse model of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)
por: Saenz, Marissa, et al.
Publicado: (2023)

Non-Alcoholic Steatohepatitis (NASH) – A Review of a Crowded Clinical Landscape, Driven by a Complex Disease
por: Fraile, Julia M, et al.
Publicado: (2021)

Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in the United Kingdom (UK) in 2018
por: Morgan, Alice, et al.
Publicado: (2021)

Investigating pharmacological mechanisms of andrographolide on non-alcoholic steatohepatitis (NASH): A bioinformatics approach of network pharmacology
por: Li, Lei, et al.
Publicado: (2021)

Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
por: Xu, Xiaohan, et al.
Publicado: (2022)

Role of Cholesterol‐Associated Steatohepatitis in the Development of NASH
por: Horn, Christian L., et al.
Publicado: (2021)

The burden of nonalcoholic steatohepatitis (NASH) in the United States
por: Tapper, Elliot B., et al.
Publicado: (2023)

Development of a Patient-Reported Outcome Measure for Non-Alcoholic Steatohepatitis (NASH-CHECK): Results of a Qualitative Study
por: Doward, Lynda C., et al.
Publicado: (2020)

Evaluation of the efficacy of mitochondrial fission inhibitor (Mdivi-1) using non-alcoholic steatohepatitis (NASH) liver organoids
por: Elbadawy, Mohamed, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ro64rsrufvm1a30e1qb722c40u